Lee M, Chung WB, Park CS, et al. - In view of the absence of a proven primary prophylactic strategy for doxorubicin-induced subclinical cardiotoxicity (DISC), particularly in patients without a cardiovascular (CV) risk, researchers herein examined the primary preventive impact of the concomitant use of angiotensin receptor blockers or beta-blockers on DISC, particularly in breast cancer patients without a CV risk. They screened 385 patients scheduled for doxorubicin chemotherapy. Of those, 195 were included and were randomly split into two categories [candesartan 4 mg q.d. vs carvedilol 3.125 mg q.d.] and controls included patients who were unwilling to receive one of the medications. Findings showed subclinical cardiotoxicity was prevalent in breast cancer patients without a CV risk treated with doxorubicin-containing chemotherapy. An early reduction in left ventricular ejection fraction might be effectively avoided via concomitant administration of low-dose candesartan in these patients.